• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

MifeMiso RCT results: Mifepristone Plus Misoprostol or Misoprostol Alone for Miscarriage Treatment?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Chu et al. (The Lancet, 2020) examined whether treatment with mifepristone plus misoprostol resulted in a higher rate of completion of missed miscarriage vs misoprostol alone

METHODS:

  • Multicenter, double-blind, placebo-controlled, randomized trial
    • Mifepristone and misoprostol versus misoprostol alone for the management of missed miscarriage (MifeMiso) Trial
  • Participants
    • ≥16 years
    • Missed miscarriage | Diagnosed by pelvic ultrasound up to 14 weeks GA
    • Patient opts for medical management of miscarriage
  • Interventions
    • Mifepristone group
      • Single 200 mg dose of oral mifepristone
      • Followed by a single dose of vaginal, oral, or sublingual misoprostol 800 μg 2 days later
    • Control group
      • Oral placebo
      • Followed by a single dose of vaginal, oral, or sublingual misoprostol 800 μg 2 days later
  • Study design
    • 1:1 randomization | Study group balancing performed for the following
      • Maternal age (<30 years vs ≥30 years)
      • Body-mass index (<35 kg/m2 vs ≥35 kg/m2)
      • Previous parity (nulliparous women vs parous women)
      • Gestational age (<70 days vs ≥70 days)
      • Amount of bleeding (Pictorial Blood Assessment Chart score; ≤2 vs ≥3)
      • Randomizing center
  • Masking: Participants, clinicians, pharmacists, trial nurses, and midwives masked to study group assignment throughout the trial
  • Power analysis: 335 women in each trial group required to provide 90% power to detect a difference of ten percentage points for primary outcome
    • Analyses based on intention-to-treat
  • Primary outcome
    • Failure to spontaneously pass the gestational sac within 7 days after assignment

RESULTS:

  • 711 women were randomized
    • Mifepristone and misoprostol group (mifepristone): 357 women
    • Placebo and misoprostol group (control): 354 women
  • Fewer women in the mifespristone group did not pass the gestational sac spontaneously within 7 days
    • Mifepristone: 17%
    • Control: 24%
    • Risk ratio (RR) 0.73 (95% CI, 0.54 to 0.99; p=0.043)
  • Fewer women in the mifepristone group required surgical intervention to complete the miscarriage
    • Mifepristone: 17%
    • Control: 25%
    • RR 0.71 (95% CI, 0.53 to 0.95; p = 0.021)
  • No subgroup effect was noted based on GA
  • Adverse events: There was no difference between groups

CONCLUSION:

  • The combination of mifepristone and misoprostol was more effective for the treatment of missed miscarriage than misoprostol alone
    • Benefits include reduced need for surgical intervention
  • The authors recommend

…women with missed miscarriage should be offered mifepristone pretreatment before misoprostol to increase the chance of successful miscarriage management, while reducing the need for miscarriage surgery

Learn More – Primary Sources:

Mifepristone and misoprostol versus misoprostol alone for the management of missed miscarriage (MifeMiso): a randomised, double-blind, placebo-controlled trial

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone

oObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

Managing Early Pregnancy Loss
Expectant Management vs Misoprostol for the Treatment of Miscarriage
Does Adding Mifepristone Prior to Misoprostol Improve Medical Management of Pregnancy Loss?
Is Surgical Evacuation Needed Following Incomplete Miscarriage?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site